Loading
This study tests a PARP inhibitor; the registry reports that it is completed.
The registry lists NCT05938270 as completed, last updated 2026-06-30. Enrolment is 113 actual participants. Interventions: Saruparib (AZD5305), Darolutamide, No Treatment. Primary measures include Fold change in % γH2AX positive cells from baseline value in tumour samples. No results are posted in the registry; this does not exclude separate publications.
Shares Saruparib, PARP, Prostate cancer.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/